Gilles Karcher
An engineer trained at Supélec and a specialist physician in Nuclear Medicine, he is a co-founder of Nancyclotep, a professor, and head of department at the CHRU of Nancy. He plays a central role in the development of Nuclear Medicine in France, notably as president of the French Society of Nuclear Medicine and the National Council of Universities.
Richard Zimmermann
A recognized expert in radiopharmacy and Nuclear Medicine, he was involved in the founding of pioneering companies such as Telix Pharma, Global Morpho Pharma, MEDraysintell, and the Oncidium foundation. His expertise in R&D and his deep knowledge of the global Nuclear Medicine industry are key assets for the development strategy and global reach of Nancyclotep and Protherium.
Richard Zimmermann
A recognized expert in radiopharmacy and Nuclear Medicine, he was involved in the founding of pioneering companies such as Telix Pharma, Global Morpho Pharma, MEDraysintell, and the Oncidium foundation. His expertise in R&D and his deep knowledge of the global Nuclear Medicine industry are key assets for the development strategy and global reach of Nancyclotep and Protherium.
Jean-Bernard Deloye
A radiopharmacist with 30 years of experience in both hospital and industrial settings, he is a co-founder of several companies specializing in short-lived radiopharmaceuticals, including Cyclopharma. Since 2021, he has been the CEO of Zionexa (GE HealthCare), overseeing clinical trials in Nuclear Medicine. He served on the board of directors of LEEM for 10 years and currently presides over the French Association of Nuclear Medicine Manufacturers.
Partners
